Novo Nordisk shareholders approve new board chair

Novo Nordisk's top shareholder, the Novo Nordisk Foundation, has asserted unprecedented control by forcing a board overhaul, installing its chairman, Lars Rebien Sorensen, as the drugmaker's new chair despite investor governance concerns over his dual role. This significant leadership change follows a tumultuous period for Novo Nordisk, characterized by profit warnings and weakening sales of its key obesity drug Wegovy due to supply constraints and intensifying competition, which Sorensen criticized the previous board for not addressing effectively.

Analysis

Novo Nordisk's top shareholder, the Novo Nordisk Foundation, has asserted unprecedented control by forcing a board overhaul, installing its chairman, Lars Rebien Sorensen, as the new chair. This move, which saw former board chair Helge Lund and independent members step down, has sparked investor protests over governance concerns, particularly regarding Sorensen's dual role and potential for concentrated power. The Foundation controls 77% of voting rights despite owning only 28% of share capital.

This significant leadership change follows a tumultuous period for Novo Nordisk, characterized by multiple profit warnings, an abrupt CEO change, and a sliding share price. The company has experienced weakening sales growth for its blockbuster obesity drug, Wegovy, due to supply constraints, commercial missteps, and intensifying competition from Eli Lilly (LLY.N). Sorensen explicitly criticized the previous board for its slow response to these declines in the key U.S. market.

Sorensen, a former Novo Nordisk CEO, plans to serve for two to three years, spearheading global layoffs and aiming to stabilize the business. His dual role, however, tests the stability typically associated with the foundation-ownership model, which is common among other large Danish firms. The market's "moderately negative" sentiment and "uncertain" tone, coupled with a -0.8 per-ticker sentiment for NVO, reflect investor apprehension regarding these governance and operational shifts.

Key Decisions for Investors

• Investors should closely monitor the impact of the new governance structure, particularly the dual role of Lars Rebien Sorensen, on long-term strategic decision-making and minority shareholder interests.
• Evaluate the effectiveness of the new leadership's operational turnaround strategy, including the impact of layoffs and efforts to address Wegovy's supply constraints and competitive pressures from Eli Lilly.
• Assess the implications of this event for the broader foundation-ownership model, as this situation challenges its perceived stability and could influence perceptions of other similarly structured companies.